The Tirzepatide Journal
The Tirzepatide Journal: Latest Research, News & Analysis
Our newest source-checked reporting on tirzepatide — clinical explainers with original charts and comparison tables, plus fast-moving FDA and market news. Every piece is written by Dr. Parmis and medically reviewed by Adam Kennah, M.D.
Latest clinical & explainer articles
Evidence-based guides built around real patient questions, each with a direct answer, a chart, and a comparison table.
How Much Weight Can You Lose on Tirzepatide? Dose-by-Dose Results15% at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg over 72 weeks in SURMOUNT-1 — chart, table, and realistic expectations.Tirzepatide Weight-Loss Timeline: What to Expect Week by WeekWhen it starts working, how loss builds through titration, and when results plateau — with a trajectory chart.Tirzepatide Beyond Weight Loss: Sleep Apnea, Diabetes & Heart (2026)Every FDA-approved indication in 2026 — diabetes, weight, sleep apnea — plus cardiovascular and liver research.Tirzepatide Side Effects: What the Clinical Trials ShowSide-effect rates from SURMOUNT-1, serious risks to know, and how titration reduces symptoms.Tirzepatide vs Semaglutide vs the New Oral Pill: 2026 ComparisonWeight loss, form, cost, and FDA status compared across injectable tirzepatide, semaglutide, and the new oral pill.
Latest news & regulatory reports
The fastest-moving stories in the tirzepatide market as of July 2026, each leading with a primary FDA or peer-reviewed source.
FDA Moves to Permanently Close 503B Compounding of TirzepatideThe April 2026 503B bulks-list proposal, the June 29 comment-period close, and what it means for patients.First GLP-1 Weight-Loss Pill Approved: What Foundayo Means for Tirzepatide PatientsFoundayo (orforglipron), approved April 1, 2026 — results, cost, and how the first oral GLP-1 pill compares.FDA Escalates Enforcement Against GLP-1 Telehealth CompoundersA 2025–2026 timeline of warning letters and enforcement against mass-marketed compounded GLP-1s.Safety Watch: Adverse Events, a New Impurity, and Counterfeits320+ adverse-event reports, a new tirzepatide-B12 impurity, counterfeits, and how to lower your risk.SURMOUNT-5: Tirzepatide Beats Semaglutide Head-to-HeadThe first direct trial: 20.2% average weight loss for tirzepatide versus 13.7% for semaglutide at 72 weeks.
Start here
All Articles →Browse the full library of tirzepatide cost, pharmacy, provider, and clinical articles.FDA & Government News →The 10 latest FDA and regulatory stories on tirzepatide and GLP-1s, each led by a primary source.Provider Rankings →Our independent six-pillar scorecard ranking online tirzepatide providers.NexLife Review (Editor’s #1) →Our full review of the top-rated provider on the scorecard.Methodology →How we research, score, and verify — and how we keep pages current.